Tackling Type 2 in COPD

Chronic obstructive pulmonary disease (COPD) is a debilitating condition that is a leading global cause of hospitalization and mortality. Type 2 inflammation is a key driver of the etiopathogenesis of COPD and involves several effector immune cells, proteins, and pathways that result in life altering symptoms such as chest tightness, fatigue, chronic coughing, wheezing, difficulty breathing, and increased mucous production that can significantly impact the ability to do daily activities. Biologic therapies that target type 2 inflammation have emerged as a clinically relevant and effective treatment option to improve symptoms, lung function, and quality of life, and reduce the occurrences of exacerbations and associated hospitalizations. Explore this exciting program that depicts the role of biologic therapies in the management of COPD and strategies for providing patient-specific, guideline driven care to optimize outcomes.